Kidney Week

Abstract: TH-PO627

Frequency of Adverse Events and Relapses after SARS-CoV-2 Vaccination in Patients with Podocytopathies

Session Information

• Membranous Nephropathy, FSGS, and Minimal Change Disease
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Lionaki, Sophia, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Sophia Lionaki, MD, PhD

• Sardeli, Angeliki, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Angeliki Sardeli, MD

• Papasotiriou, Marios, Panepistemio Patron, Patra, Periféria Dhitikís Elládh, Greece

Marios Papasotiriou, MD, PhD

• Dounousi, Evangelia, Panepistemio Ioanninon, Ioannina, Epirus, Greece

Evangelia Dounousi, MD, PhD

• Marinaki, Smaragdi, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Greece

Smaragdi Marinaki, MD

• Pelagia, Kriki, Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece

Kriki Pelagia

• Gkalitsiou, Dimitra, Geniko Nosokomeio Athenon Giorgos Gennematas, Athens, Attike, Greece

Dimitra Gkalitsiou, DrMed

• Liakopoulos, Vassilios, Aristoteleio Panepistemio Thessalonikes, Thessalonike, Kentrikḗ Makedonía, Greece

Vassilios Liakopoulos, MD, PhD

• Andronikidi, Eva Paraskevi, Ethniko kai Kapodistriako Panepistemio Athenon, Athens, Attica, Greece

Eva Paraskevi Andronikidi, MD

• Panagiotis, Giannakopoulos, Panepistemiako Geniko Nosokomeio Attikon, Athens, Attica, Greece

Giannakopoulos Panagiotis, MD

• Panagoutsos, Stylianos A., Demokriteio Panepistemio Thrakes, Komotini, East Macedonia and Thrace, Greece

Stylianos A. Panagoutsos, MD

Background

To evaluate the impact, if any, of SARS-CoV-2 vaccination in the clinical course of patients with biopsy-proven podocytopathies.

Methods

This is a multicenter retrospective study of patients with histologically proven minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS), who were vaccinated against SARS-CoV-2. Patients who had developed ESKD prior to vaccine were excluded. Recorded data included adverse events, immunosuppressive regimens and relapses of the primary disease.

Results

Included patients (N=77) patients were 46.1(±17.8) years old and 38(49.3%) were males. Of these, 68(88.3%) patients had received immunosuppression at diagnosis and 80.5% had achieved remission. The time interval from kidney biopsy to vaccination was 69.2(±75.8) months and received 2.9(±0.76) doses. 37.3% of patients were on immunosuppressive therapy at vaccination. 25.3% of patients reported systemic and 31.8% local adverse events associated with vaccination. Among patients on remission at vaccination, 8(10.4%) experienced a relapse of nephrotic syndrome within 3.5 (±2.7) months. Among relapsers, 5 (71.4%%) had MCD.

Conclusion

Patients with podocytopathies in this cohort had a good vaccine safety profile. Among patientson remission 8(10.4%) experienced a relapse of the primary disease after vaccination.